Is Compounded Semaglutide Still Legal in 2026? The Honest Answer
Key Takeaways
- Yes — compounded semaglutide is still legal in the U.S. as of July 2026, but under tighter restrictions
- Only patient-specific (503A) compounding with a valid individual prescription remains clearly legal
- 503B outsourcing facilities face increasing FDA scrutiny — their legal standing depends on shortage status
- Semaglutide is no longer on the FDA drug shortage list, which limits the basis for bulk compounding
- Salt forms (semaglutide sodium, semaglutide acetate) are considered different drugs by the FDA and not approved
The legal landscape for compounded semaglutide has shifted dramatically since 2024. What was once a straightforward shortage-based compounding pathway is now a complex regulatory situation. Here's where things actually stand.
The Current Legal Framework
Compounding of drugs in the U.S. is governed by two main pathways under the Federal Food, Drug, and Cosmetic Act:
| Pathway | Section | Requirements | 2026 Status for Semaglutide |
|---|---|---|---|
| 503A (traditional compounding) | FDCA §503A | Individual prescription, licensed pharmacy, patient-specific | Legal with valid Rx |
| 503B (outsourcing facility) | FDCA §503B | FDA-registered, can compound without individual Rx during shortage | Restricted — shortage ended |
What Changed
When semaglutide was on the FDA drug shortage list (2022–2024), both 503A and 503B pharmacies had broad legal cover to compound it. When the shortage ended, 503B facilities lost their primary legal basis for bulk compounding without individual prescriptions. 503A pharmacies can still compound semaglutide with a valid patient-specific prescription — that pathway was never dependent on shortage status.
Some compounding pharmacies use semaglutide sodium or semaglutide acetate instead of the base form. The FDA considers these different chemical entities — not interchangeable with the approved semaglutide base. Compounding with salt forms faces additional legal risk because the FDA argues these have never been approved in any form.
What This Means for Patients
If you're currently using compounded semaglutide from a 503A pharmacy with a valid prescription, your access is legally sound. The providers below work through licensed 503A compounding pharmacies with patient-specific prescriptions.
Embody
GLP-1 · LeadCompounded injectable semaglutide. Established program, strong clinical support. Lead anchor provider.
Gala
GLP-1Compounded injectable semaglutide at $179/month flat pricing. Injection-only.
GobyMeds
BudgetInjectable compounded sema $99/mo, tirz $133/mo. Direct affiliate.
Compounded semaglutide is legal in 2026 through the 503A patient-specific pathway with a valid prescription. The legal risk sits primarily with 503B outsourcing facilities and salt-form compounds. If your provider uses a licensed 503A pharmacy and your prescription is individual and valid, you're on solid legal ground.
Legal analysis based on publicly available FDA guidance and FDCA text as of July 2026. This is not legal advice. Regulatory landscape may change.
GLP-1 Compound Pharmacy Editorial
Independent compounding pharmacy research. 503A/503B analysis, safety verification, regulatory tracking. Not medical advice.